Posts by: Alice Melão

News

More than half of all deaths related to asbestos exposure is caused by malignant mesothelioma, a new study has shown. The study, “Risk Factors of Mortality from All Asbestos-Related Diseases: A ... Read more

August 4, 2017August 4, 2017

Lymphoma Patients Who Receive Radiotherapy at Higher Risk of Developing Mesothelioma, Study Shows

News

People who have radiotherapy to treat lymphoma are more likely to develop malignant mesothelioma, especially if they were diagnosed before 1995 and were younger at diagnosis, a study reports. The ... Read more

August 1, 2017

Case Study of Malignant Mesothelioma of the Liver and Greater Omentum May be a First

News

The most common form of malignant mesothelioma arises from the pleura – the lining membrane that covers the lungs — and is usually due to asbestos exposure. But this disease ... Read more

July 24, 2017July 24, 2017

P/D Surgery Less Detrimental to MPM Patients’ Quality of Life Than EPP, Study Finds

News

Malignant pleural mesothelioma (MPM) patients who undergo pleurectomy (P/D) surgery usually live better and longer lives than those who have extrapleural pneumonectomy (EPP) surgery, finds a study featured in the Annals of Translational Medicine. ... Read more

July 12, 2017July 12, 2017

Mutations in DNA Repair Genes Linked to Likelihood of Mesothelioma Upon Asbestos Exposure in Study

News

Inherited mutations in the genes responsible for the maintenance and repair of a cell’s DNA can help explain why some people develop malignant pleural mesothelioma (MPM) upon asbestos exposure while others don’t. ... Read more

June 21, 2017

Combining Immunotherapy, Accelerated Radiation and Surgery Bolsters Immune Response Against Mesothelioma, Study Shows

News

Combining immunotherapy, accelerated radiation and surgery can improve immune system response against malignant pleural mesothelioma, according to a study. Immunotherapies for solid tumors have become a major focus of cancer research, ... Read more

June 6, 2017

Opdivo, Yervoy Combo Seem More Effective Than Standard Therapies in Relapsed MPM

News

Immunotherapy may be the way to tackle malignant pleural mesothelioma (MPM) after relapse, a new Phase 2 trial suggests. Using Opdivo (nivolumab) alone or in combination with Yervoy (ipilimumab) was found to ... Read more

May 26, 2017May 26, 2017

ADI-PEG 20 Seen to Improve Response to Chemo in MPM Patients in Extension Trial

News

Results from a Phase 1 extension study further confirmed the potential of ADI-PEG 20 to enhance the effectiveness of two chemotherapies — Platinol (cisplatin) and Alimta (pemetrexed) — commonly used to treat ... Read more

May 17, 2017May 17, 2017

Mesothelin Protein Expression Can Help Predict Mesothelioma Patients’ Survival, Study Reports

News

The more mesothelioma tumor cells that express the mesothelin protein, the longer a patient is likely to live, according to a study. That finding is the opposite of the connection ... Read more

May 15, 2017May 15, 2017

Simultaneous Inhibition of Two Cell Pathways Prevents Mesothelioma Tumor Growth, Study Finds

News

The diabetes treatment metformin could be combined with a therapy that inhibits thet MDM2 protein to suppress the growth of malignant mesothelioma cells, a study reports. Researchers said the findings have shed ... Read more